LivingTrust Mortgage Bank Plc (OMOLU.ng) listed on the Nigerian Stock Exchange under the Banking sector has released it’s 2018 annual report.For more information about LivingTrust Mortgage Bank Plc (OMOLU.ng) reports, abridged reports, interim earnings results and earnings presentations, visit the LivingTrust Mortgage Bank Plc (OMOLU.ng) company page on AfricanFinancials.Document: LivingTrust Mortgage Bank Plc (OMOLU.ng) 2018 annual report.Company ProfileLivingTrust Mortgage Bank Plc, formerly Omoluabi Mortgage Bank Plc is a financial services institution in Nigeria offering banking products and services for the retail, commercial and corporate sectors. The company specialises in mortgage financing and provides products which include national housing fund mortgage loans, commercial mortgages, property acquisition loans and loans for the business, construction and trading sectors. Omoluabi Mortgage Bank Plc also offers a range of banking products and services for the personal banking sector which includes transactional accounts, call accounts, term and fixed deposits, certificate of deposits and housing investment funds. Corporate banking products include overdraft facilities and property development financing and trading. Formerly known as Omoluabi Savings and Loans Plc, the company changed its name to Omoluabi Mortgage Bank Plc in 2016. Its major shareholders are Osun State Government and two major institutional investors. The company’s head office is in Lagos, Nigeria. LivingTrust Mortgage Bank Plc is listed on the Nigerian Stock Exchange
ArchDaily Projects Houses Year: Area: 3700 ft² Year Completion year of this architecture project 2010 “COPY” Potrero House / Cary Bernstein ArchitectSave this projectSavePotrero House / Cary Bernstein Architect Architects: Cary Bernstein Architect Area Area of this architecture project Potrero House / Cary Bernstein Architect CopyHouses•San Francisco, United States CopyAbout this officeCary Bernstein ArchitectOfficeFollowProductWood#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesDabasSan FranciscoWoodHouses3D ModelingUnited StatesPublished on March 25, 2011Cite: “Potrero House / Cary Bernstein Architect” 25 Mar 2011. ArchDaily. Accessed 12 Jun 2021.
By Gary Truitt – Jan 25, 2015 Facebook Twitter Home Indiana Agriculture News Neonicotinoid Seed Treatments Critical for Certain Soybean Operations SHARE In comments submitted to the U.S. Environmental Protection Agency today, the American Soybean Association (ASA) disagreed with the conclusions of a recent report from EPA that calls into question the efficacy of neonicotinoid seed treatments in soybean operations. In the association’s comments, ASA President and Brownfield, Texas, farmer Wade Cowan pointed out that “…soybean producers use neonicotinoid seed treatments where they are needed and effective, and don’t use them where not.” Cowan also argued that recent research from Mississippi showing approximately 90 percent adoption of neonicotinoid seed treatments signals that the technology does work for farmers in certain areas.In the comments, Cowan noted that neonicotinoid seed treatment use is tailored to a very specific set of circumstances, and in those settings, that particular technology is critical, “Farmers balance the efficacy of different treatments based on their individual farms, and experience shows that farmers who purchase seed treatment for soybeans do so because it reduces or eliminates the need for application of additional inputs after the soybean seedling has emerged,” he said. “Seed treatments both protect the soybeans from insects in the soil after planting as well as protecting the seedlings as they emerge. A below-ground insect infestation has no rescue options except replanting, and in the northern growing regions, replanting is not often an option.”“EPA must not allow political pressure to lead to restrictions on crop protection tools,” concluded Cowan. “We have appreciated EPA’s science-based decision-making in evaluating crop protection products, particularly as they are wrongly singled out as the cause of pollinator decline. We urge EPA to maintain its commitment to science in evaluating crop protection tools.”A full transcript of ASA’s comments can be downloaded here. Facebook Twitter Neonicotinoid Seed Treatments Critical for Certain Soybean Operations SHARE Previous articleClosing CommentsNext articleSunday Outlook Gary Truitt
Ovidiu Dugulan/iStockBy MORGAN WINSOR, ERIN SCHUMAKER, IVAN PEREIRA and EMILY SHAPIRO, ABC News(NEW YORK) — A pandemic of the novel coronavirus has now infected more than 65.4 million people and killed over 1.5 million worldwide, according to real-time data compiled by the Center for Systems Science and Engineering at Johns Hopkins University.Here’s how the news is developing Friday. All times Eastern:Dec 04, 10:09 amAfrica aims to vaccinate 60% of population in 2-3 yearsAfrica aims to have 60% of its 1.2 billion-strong population vaccinated against COVID-19 within the next two to three years, according to the head of the continent’s public health agency.“We hope that for that for this to be meaningful, our 60% must be reached in the next two to three years,” John Nkengasong, director of the Africa Centers for Disease Control and Prevention, said at a press briefing Thursday. “We should be deliberate in this.”More than 2.2 million confirmed cases of COVID-19, including over 52,000 deaths, have been reported across the vast continent so far, representing a fraction of the world’s cumulative count.Dec 04, 8:59 amMoscow launches mass COVID-19 vaccination programMoscow Mayor Sergey Sobyanin announced Friday the official start of a mass COVID-19 vaccination program in the Russian capital.Residents are now able to sign up online to be vaccinated, and Sobyanin said some 5,000 people had registered in the first five hours since the launch.“Teachers, doctors, social workers, those who today most of all risk their health and lives,” the mayor wrote in a brief post on his blog Friday.The announcement comes two days after Russian President Vladimir Putin unexpectedly ordered large-scale vaccination to start next week, despite earlier statements from the government saying the country has yet to produce enough vaccine doses to do so.The mass inoculation campaigns will use Russia’s COVID-19 vaccine, called Sputnik V, which the health ministry controversially registered in August before starting crucial late-stage clinical trials. Vaccinations will be voluntary, with the drives first focusing on teachers and doctors.Russia was still vaccinating volunteers as part of its phase 3 trial, which has so far only managed to inoculate 20,000 of a planned 40,000 people.Putin has said that Russia will soon produce two million doses of Sputnik V, but it’s unclear how many doses have been been produced so far and how many people will be able to be vaccinated next week. The country has run into serious manufacturing hurdles and had to significantly cut its planned production from 30 million to two million by the end of the year.Dec 04, 7:31 amCOVID-19 vaccinations will be free of charge in FranceFrench Prime Minister Jean Castex said COVID-19 vaccinations will not be made compulsory but “will be free for all” in the country’s social security system.“Getting a vaccine is also about protecting others. It is a choice of trust, we must be as numerous as possible to get a vaccine,” Castex said at a press conference Thursday evening, while unveiling the country’s vaccination strategy.France will launch a COVID-19 vaccination campaign within weeks, pending regulatory approval by the European Medicines Agency. The program will run throughout 2021, staggered over three categories of people.The first phase is slated to begin in January, with vaccines administered to nursing home residents and staff, representing one million people. A second phase starting in February will see 14 million people inoculated, based on age and medical criteria. The third and final phase, beginning in March, will target the remainder of the population who wish to be vaccinated.Through deals clinched by the European Union, France has secured some 200 million doses of COVID-19 vaccines from several pharmaceutical companies and biotechnology firms that developed them and have applied for temporary authorization. Castex said that’s enough doses to inoculate 100 million people — more than France’s entire population.As of Friday afternoon, France’s health ministry had confirmed a total of 2,257,331 cases of COVID-19 since the start of the pandemic, including 54,140 deaths.Dec 04, 5:18 amItaly reports nearly 1,000 new deaths in all-time highAn additional 993 deaths from COVID-19 were registered in Italy on Thursday, marking a new all-time high, according to data from the country’s civil protection agency.Italy’s previous single-day record of 969 new fatalities from the disease was set in late March, when the country was the epicenter of the pandemic in Europe.The Italian civil protection agency also reported 23,225 newly confirmed cases of COVID-19 and 31,772 patients currently hospitalized with the disease, including 3,597 in intensive care.Since the start of the pandemic, Italy has confirmed more than 1,664,829 million cases, including at least 58,038 deaths, according to the civil protection agency.The country has the eighth highest case load in the world, according to a real-time count kept by Johns Hopkins University.Dec 04, 4:17 amUS has worst day yet with record number of new cases and deathsThere were 217,664 newly confirmed cases of COVID-19 and 2,879 additional deaths from the disease registered in the United States on Thursday, both numbers which shattered the country’s previous daily records, according to a real-time count kept by Johns Hopkins University.It’s the most new cases and deaths the U.S. has recorded in a single day since the start of the coronavirus pandemic. It’s also the 31st straight day that the country has reported over 100,000 newly diagnosed infections, and the third time since the pandemic began that the daily figure has topped 200,000, according to Johns Hopkins data.COVID-19 data may be skewed in the coming days and weeks due to possible lags in reporting over Thanksgiving followed by a potentially very large backlog from the holiday.A total of 14,143,801 people in the U.S. have been diagnosed with COVID-19 since the pandemic began, and at least 276,366 of them have died, according to Johns Hopkins data. The cases include people from all 50 U.S. states, Washington, D.C., and other U.S. territories as well as repatriated citizens.Much of the country was under lockdown by the end of March as the first wave of pandemic hit. By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country’s cases then hovered around 20,000 for a couple of weeks before shooting back up over the summer.The numbers lingered around 40,000 to 50,000 from mid-August through early October before surging again to record levels, crossing 100,000 for the first time on Nov. 4 and reaching 200,000 for the first time on Nov. 27.Copyright © 2020, ABC Audio. All rights reserved.
View post tag: FS Floreal View post tag: Operation Atalanta Authorities February 11, 2016 Operation Atalanta flagship ITS Carabiniere conducted a joint exercise with the French frigate FS Floreal in the waters off Seychelles’ main harbour on February 5, 2016.The exercise was coordinated by the ships’ commanding officers, Commander François Xavier Waroux and Commander Francesco Saladino. The training tested the ships’ crews and included close-proximity manoeuvres, visual communications, flight operations and helicopter landings.Rear Admiral Stefano Barbieri, Operation Atalanta’s Force Commander, said: “The cooperation between multi-national navies is critical to counter the piracy threat to maritime routes.”Having raised her anchor at dawn, ITS Carabiniere steamed to the training area to meet FS Floreal. The French frigate is permanently based in La Réunion, an island in the French insular region in the Indian Ocean, and is tasked with combating piracy, illegal fishing and counter narcotics. After a full day’s exercise, both ships departed the exercise area to continue their respective tasks.Joint training and exercises such as this strengthen multi-national efforts to deter and disrupt piracy in the Indian Ocean.[mappress mapid=”17693″] View post tag: ITS Carabiniere Back to overview,Home naval-today ITS Carabiniere, FS Floreal train in waters off Seychelles ITS Carabiniere, FS Floreal train in waters off Seychelles Share this article
“My memory of the incident is a bit hazy, but I remember that there were two people I didn’t know having an argument and it got heated. I attempted to intervene and for my trouble I was punched so hard it knocked me out.“I’ve never been hit before and I was in A&E for six hours that night. I’m quite light-hearted about the whole thing but it was so avoidable.”The police are still investigating both incidents but there have been no arrests made so far. The rapid spate of attacks since the beginning of term has raised concerns that students are being deliberately targeted.Osborn agreed that the attack felt like more than a straightforward mugging. He said, “Once they took my things they argued about what they were going to do with me. They decided to hit me anyway even though they’d already robbed me.“I live in a very rough area of London, and I’ve been mugged before, but I’ve never had an experience as horrible as that. It didn’t seem like they needed to steal. It just seemed like they wanted to hurt me. When I was assaulted before it was a means to an end – they hit me first and then took my wallet. I just got the impression that they hated me.”A further incident was reported to police on the same evening that Osborn was attacked. A 23-year-old student was admitted to hospital after being hit with a glass bottle at the corner of South Parks Road and St Cross Road. The man was walking with friends when confronted by a larger group of people at around 10.45pm.The incident is also being treated as grievous bodily harm but no-one has been arrested.Both Osborn and Maconnachie have praised police assistance. Maconnachie commented, “When I came around the police were already there and somebody had called an ambulance for me.”Osborn said, “The police have been very helpful. They explained that I’ll be entitled to compensation because it was a case of grievous bodily harm.”Tom Perry, OUSU Welfare warned that students must not underestimate the dangers of walking alone late at night. He commented, “While Oxford may seem like a quaint place to live, it is a city, and students should be careful.”Last week, an Oxford Brookes student was stabbed outside the O2 Academy on Cowley Road. A man has now been arrested for the attack.Benjamin Hepburn, 22, appeared at Oxford Magistrates’ Court last week and will appear at Oxford Crown Court later today. He has been charged with causing grievous bodily harm with intent. Fears about student safety have been raised this week following three violent assaults in central Oxford.These latest attacks follow two stabbings Cowley last week.Third year student Laurence Osborn was robbed by a group of five men on Parks Road, opposite Keble college, leaving him with severe head injuries.“I was walking into the centre of town for a friend’s birthday when I saw a group of guys on bikes and a moped coming towards me on the pavement rather than the road. I didn’t think for a moment that I was a target because I was so close to town.”The group pushed Osborn against a wall and threatened physical violence unless he handed over his phone. Osborn complied but the attackers decided the phone wasn’t valuable enough to steal and broke it instead.After punching him, the group began to move away. However, when Osborn stayed to attempt to retrieve his glasses from the ground, the attackers threw a bottle at him and forced Osborn to run in the direction of The King’s Arms.Despite his injuries, Osborn commented, “It’s more psychologically wounding than physically wounding. I’ve been having flashbacks, but I’m alright. I’m not going to let it affect the academic year and my tutors have been supportive.”The attack left Osborn with a broken nose and fractured cheek. He was admitted to A&E because of blood clots and worries that the compound breakage of bone as well as cartilage in the nose was consistent with skull fracture.Although the attack occurred at nine o’clock at night, no passers-by witnessed the incident, and Osborn’s attackers made off with his passport, bank cards and keys. The student was forced to remove any valuables from his college room and sleep elsewhere until the lock was changed.A second student, Ian Maconnachie, was assaulted on his way home from Park End last Wednesday. The attack took place outside O’Neill’s pub on New Inn Hall Street at around 3am.
On 30 April, the University of Oxford announced a partnership with biopharmaceutical company AstraZeneca for global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The partnership aims to bring the ChAdOx1 nCoV-19 vaccine to patients if the vaccine becomes distributable. The vaccine candidate is being trialled by the University’s Jenner Institute and Oxford Vaccine Group. The coronavirus vaccine development began in January 2020. The partnership will prepare for future pandemics and attempt to increase the speed with which such challenges are addressed. By creating the framework for future development, the University and AstraZeneca hope to improve responses to future pandemics. In AstraZeneca’s announcement, Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said: “Our partnership with AstraZeneca will be a major force in the struggle against pandemics for many years to come. We believe that together we will be in a strong position to start immunising against coronavirus once we have an effective approved vaccine. Sadly, the risk of new pandemics will always be with us and the new research centre will enhance the world’s preparedness and our speed of reaction the next time we face such a challenge.” The Oxford University announcement states: “Oxford University and its spin-out company Vaccitech, who jointly have the rights to the platform technology used to develop the vaccine candidate, will receive no royalties from the vaccine during the pandemic. Any royalties the University subsequently receives from the vaccine will be reinvested directly back into medical research, including a new Pandemic Preparedness and Vaccine Research Centre. The centre is being developed in collaboration with AstraZeneca.” The spokesperson continued: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. The Jenner Institute proved in previous trials that the same vaccine platform had shown promise in early clinical trials. This means they have been able to develop the potential COVID-19 vaccine and advance to clinical trials more quickly. AstraZeneca will be working closely with the University, governments, health authorities and CMOs over the coming weeks and months to ensure we can accelerate the development and manufacturing as quickly as possible.” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “The University of Oxford and AstraZeneca have a longstanding relationship to advance basic research and we are hugely excited to be working with them on advancing a vaccine to prevent COVID-19 around the world. We are looking forward to working with the University of Oxford and innovative companies such as Vaccitech, as part of our new partnership.” If the University’s vaccine candidate is successful, AstraZeneca will be in charge of development, global manufacturing, and distribution of the vaccine. AstraZeneca will work to make the vaccine available in conjunction with global partners – with a focus on making the vaccine available and accessible to low- and medium-income countries. In a comment to Cherwell, an AstraZeneca spokesperson said: “The University of Oxford and AstraZeneca have a longstanding relationship to advance research and scientific understanding of complex diseases. By partnering we want to combine Oxford’s world-class expertise in vaccinology with AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.” The partnership aims to increase the speed with which the vaccine – if successful – could reach patients worldwide. Oxford University’s Vice-Chancellor, Professor Louise Richardson, expressed her excitement about and approval of the AstraZeneca partnership. “Like my colleagues all across Oxford, I am deeply proud of the work of our extraordinarily talented team of academics in the Jenner Institute and the Oxford Vaccine Group. They represent the best tradition of research, teaching and contributing to the world around us, that has been the driving mission of the University of Oxford for centuries. Like people all across the country, we are wishing them success in developing an effective vaccine. If they are successful, our partnership with AstraZeneca will ensure that the British people and people across the world, especially in low and middle income countries, will be protected from this terrible virus as quickly as possible.” The partnership is to be the first of its kind since the government launched a dedicated Vaccines Taskforce – aimed at finding, testing and delivering a new coronavirus vaccine. It comes alongside £20 million in government funding for the University’s vaccine research and clinical trials. Both AstraZeneca and the University have agreed to operate on a not-for-profit basis during the coronavirus pandemic. Image Credit to: fernandozhiminaicela/Pixabay
While no definitive party has been identified as being responsible for the situation, confusion may have resulted from a list posted on the National Careers Service website that included early years providers, including nursery staff and childminders, as social care workers who were included in this phase of the roll out and were therefore offered appointments for jabs. Frontline community healthcare workers have already been given their vaccinations. Nonetheless, those who were turned away expressed their frustration. A nursery worker Karen Ratcliff, 62 from Wantage was also turned away, and told the Oxford Mail: “Girls have had their holidays cancelled, they book a week off at home and then have to come in. We look after all these kids. It is really upsetting, I usually work part-time but I have been working full-time. I am 62, I do not want to be working full-time anymore. It is exhausting.” An early years teacher from a north Oxford school called the system “chaotic shambles” for instance after being forced to leave on Saturday evening and a member of staff estimates that “at least 200 people” were turned away on Saturday alone, many of them having driven long distances from around the county. The teacher told the Oxford Mail: “I am so angry. They have given people false hope and wasted our time. They had our contact details but made no attempt to let us know, which is a basic courtesy. They would rather sit back, let hundreds of people turn up and turn them away in the car park. Early year providers are working throughout the pandemic and are struggling at high risk without the financial support to buy appropriate PPE and sanitising products. Pre-schools have been open since September and we are all worried and anxious. Mistakes like this should not happen. The lack of respect for the early years sector is unforgivable. And we haven’t been given any indication of when we can actually get our jabs.” Hundreds of individuals reported being turned away from Oxford’s Kassam Stadium COVID-19 vaccination hub on the weekend of February 13th because of a booking error where some social care professionals who were offered jab appointments were then told there is no vaccine for them. Oxfordshire County Council asserted that these early staff should not have access to jabs and a spokesperson for Oxford Health NHS Foundation Trust commented: “We continue to vaccinate people in priority cohorts set by the JCVI, and local authorities are identifying eligible social care staff. People who booked in error are rightly asked to wait their turn so that we can prioritise those eligible for vaccination at this time, including older residents and those who are clinically vulnerable. We are carrying out ID checks at the Vaccination Centre to ensure only those who are currently eligible are vaccinated.” Image: Steven Cornfeld via unsplash.com